Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

ABSTRACT:

Background

Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma.

Methods

We conducted an open-label, multicenter, randomized phase 3 trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma, in which 664 were assigned to receive brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) and 670 were assigned to receive doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The primary end point was modified progression-free survival (the time to progression, death, or noncomplete response and use of subsequent anticancer therapy) as adjudicated by an independent review committee. The key secondary end point was overall survival.

Results

A

SUBMITTER: Connors JM 

PROVIDER: S-EPMC5819601 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature